What's new in the toolbox for constipation and fecal incontinence?

Frontiers in Medicine

Volumn 1, Issue MAR, 2014, Pages

  Lee, Yeong Yeh ^a,b  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Anorectal disorders; Constipation; Fecal incontinence; Management; Pathophysiology

Indexed keywords

EID: 85012066639     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2014.00005     Document Type: Review

References (111)

1. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol (2011) 106:1582-91. doi: 10.1038/ajg.2011.164
2. Leung FW, Rao SSC. Fecal incontinence in the elderly. Gastroenterol Clin North Am (2009) 38:503-11. doi:10.1016/j.gtc.2009.06.007
3. Dunivan GC, Heymen S, Palsson OS, von Korff M, Turner MJ, Melville JL, et al. Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization. Am J Obstet Gynecol (2010) 202:.e1-6. doi:10.1016/j.ajog.2010.01.018
4. Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm (2013) 19:755-64
5. Bharucha AE, Wald A, Enck P, Rao S. Functional anorectal disorders. Gastroenterology (2006) 130:1510-8. doi:10.1053/j.gastro.2005.11.064
6. Whitehead WE, Wald A, Diamant NE, Enck P, Pemberton JH, Rao SS. Functional disorders of the anus and rectum. Gut (1999) 45(Suppl 2):II55-9. doi:10.1136/gut.45.2008.ii55
7. Rao SSC. Diagnosis and management of fecal incontinence. American college of gastroenterology practice parameters committee. Am J Gastroenterol (2004) 99:1585-604. doi:10.1111/j.1572-0241.2004.40105.x
8. Stewart WF, Liberman JN, Sandler RS, Woods MS, Stemhagen A, Chee E, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol (1999) 94:3530-40. doi:10.1111/j.1572-0241.1999.01642.x
9. van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol (2006) 101:2401-9. doi:10.1111/j.1572-0241.2006.00771.x
10. van Ginkel R, Reitsma JB, Büller HA, van Wijk MP, Taminiau JAJM, Benninga MA. Childhood constipation: longitudinal follow-up beyond puberty. Gastroenterology (2003) 125:357-63. doi:10.1016/S0016-5085(03)00888-6
11. Whitehead WE, Borrud L, Goode PS, Meikle S, Mueller ER, Tuteja A, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology (2009) 137:512-7. doi:10.1053/j.gastro.2009.04.054
12. Leung FW, Schnelle JF. Urinary and fecal incontinence in nursing home residents. Gastroenterol Clin North Am (2008) 37:697-707. doi:10.1016/j.gtc.2008.06.005
13. Rao SSC, Ozturk R, Stessman M. Investigation of the pathophysiology of fecal seepage. Am J Gastroenterol (2004) 99:2204-9. doi:10.1111/j.1572-0241.2004.40387.x
14. Rao SS, Sadeghi P, Batterson K, Beaty J. Altered periodic rectal motor activity: a mechanism for slow transit constipation. Neurogastroenterol Motil (2001) 13:591-8. doi:10.1046/j.1365-2982.2001.00292.x
15. Preston DM, Lennard-Jones JE. Severe chronic constipation of young women: "idiopathic slow transit constipation". Gut (1986) 27:41-8. doi:10.1136/gut.27.1.41
16. Attaluri A, Jackson M, Valestin J, Rao SSC. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol (2010) 105:1407-11. doi:10.1038/ajg.2009.655
17. Chatterjee S, Park S, Low K, Kong Y, Pimentel M. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol (2007) 102:837-41. doi:10.1111/j.1572-0241.2007.01072.x
18. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci (2006) 51:1297-301. doi:10.1007/s10620-006-9104-6
19. Rao SSC, Sadeghi P, Beaty J, Kavlock R. Ambulatory 24-hour colonic manometry in slow-transit constipation. Am J Gastroenterol (2004) 99:2405-16. doi:10.1111/j.1572-0241.2004.40453.x
20. Gladman MA, Lunniss PJ, Scott SM, Swash M. Rectal hyposensitivity. Am J Gastroenterol (2006) 101:1140-51. doi:10.1111/j.1572-0241.2006.00604.x
21. Chiarioni G, Salandini L, Whitehead WE. Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. Gastroenterology (2005) 129:86-97. doi:10.1053/j.gastro.2005.05.015
22. Lee YY, Erdogan A, Rao SSC. High resolution and high definition anorectal manometry and pressure topography: diagnostic advance or a new kid on the block? Curr Gastroenterol Rep (2013) 15:360. doi:10.1007/s11894-013-0360-2
23. Cheeney G, Remes-Troche JM, Attaluri A, Rao SSC. Investigation of anal motor characteristics of the sensorimotor response (SMR) using 3-D anorectal pressure topography. Am J Physiol Gastrointest Liver Physiol (2011) 300:G236-40. doi:10.1152/ajpgi.00348.2010
24. Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M. Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol (2012) 107:754-60. doi:10.1038/ajg.2012.5
25. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology (1995) 109:40-52. doi:10.1016/0016-5085(95)90267-8
26. Tanaka Y, Kanazawa M, Fukudo S, Drossman DA. Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil (2011) 17:131-9. doi:10.5056/jnm.2011.17.2.131
27. Simrén M, Barbara G, Flint HJ, Spiegel BMR, Spiller RC, Vanner S, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut (2013) 62:159-76. doi:10.1136/gutjnl-2012-302167
28. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology (2006) 130:34-43. doi:10.1053/j.gastro.2005.09.031
29. Costedio MM, Coates MD, Brooks EM, Glass LM, Ganguly EK, Blaszyk H, et al. Mucosal serotonin signaling is altered in chronic constipation but not in opiate-induced constipation. Am J Gastroenterol (2010) 105:1173-80. doi:10.1038/ajg.2009.683
30. Shekhar C, Monaghan PJ, Morris J, Issa B, Whorwell PJ, Keevil B, et al. Rome III functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology (2013) 145:749-57. doi:10.1053/j.gastro.2013.07.014
31. Markland AD, Palsson O, Goode PS, Burgio KL, Busby-Whitehead J, Whitehead WE. Association of low dietary intake of fiber and liquids with constipation: evidence from the national health and nutrition examination survey. Am J Gastroenterol (2013) 108:796-803. doi:10.1038/ajg.2013.73
32. Schnelle JF, Leung FW, Rao SSC, Beuscher L, Keeler E, Clift JW, et al. A controlled trial of an intervention to improve urinary and fecal incontinence and constipation. J Am Geriatr Soc (2010) 58:1504-11. doi:10.1111/j.1532-5415.2010.02978.x
33. Ford AC, Suares NC. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut (2011) 60:209-18. doi:10.1136/gut.2010.227132
34. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst Rev (2007) 4:CD003960. doi:10.1002/14651858.CD003960.pub3
35. Mansour NM, Ghaith O, El-Halabi M, Sharara AI. A prospective randomized trial of mosapride vs. placebo in constipation-predominant irritable bowel syndrome. Am J Gastroenterol (2012) 107:792-3. doi:10.1038/ajg.2012.26
36. Scarpellini E, Tack J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs (2008) 17:1663-70. doi:10.1517/13543784.17.11.1663
37. Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murad MH. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther (2013) 39:239-53. doi:10.1111/apt.12571
38. Chan WW, Mashimo H. Lubiprostone increases small intestinal smooth muscle contractions through a prostaglandin E receptor 1 (EP1)-mediated pathway. J Neurogastroenterol Motil (2013) 19:312-8. doi:10.5056/jnm.2013.19.3.312
39. Camilleri M, Bharucha AE, Ueno R, Burton D, Thomforde GM, Baxter K, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 290:G942-7. doi:10.1152/ajpgi.00264.2005
40. Lembo AJ, Johanson JF, Parkman HP, Rao SS, Miner PB, Ueno R. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci (2011) 56:2639-45. doi:10.1007/s10620-011-1801-0
41. Andresen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKinzie S, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 133:761-8. doi:10.1053/j.gastro.2007.06.067
42. Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci (2010) 86:760-5. doi:10.1016/j.lfs.2010.03.015
43. Videlock EJ, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. Clin Gastroenterol Hepatol (2013) 11:1084.e-92.e. doi:10.1016/j.cgh.2013.04.032
44. Rao SSC, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol (2007) 5:331-8. doi:10.1016/j.cgh.2006.12.023
45. Rao SSC, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol (2010) 105:890-6. doi:10.1038/ajg.2010.53
46. Rao SSC. Dyssynergic defecation and biofeedback therapy. Gastroenterol Clin North Am (2008) 37:569-86. doi:10.1016/j.gtc.2008.06.011
47. Kunkel D, Basseri RJ, Makhani MD, Chong K, Chang C, Pimentel M. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci (2011) 56:1612-8. doi:10.1007/s10620-011-1590-5
48. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut (2010) 59:325-32. doi:10.1136/gut.2008.167270
49. Quigley EMM. Probiotics in the management of functional bowel disorders: promise fulfilled? Gastroenterol Clin North Am (2012) 41:805-19. doi:10.1016/j.gtc.2012.08.005
50. Miller LE, Ouwehand AC. Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials. World J Gastroenterol (2013) 19:4718-25. doi:10.3748/wjg.v19.i29.4718
51. Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J Gastroenterol (2010) 16:69-75. doi:10.3748/wjg.v16.i1.69
52. Korterink JJ, Ockeloen L, Benninga MA, Tabbers MM, Hilbink M, Deckers-Kocken JM. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatr (2014) 103(4):365-72. doi:10.1111/apa.12513
53. Reshef A, Alves-Ferreira P, Zutshi M, Hull T, Gurland B. Colectomy for slow transit constipation: effective for patients with coexistent obstructed defecation. Int J Colorectal Dis (2013) 28:841-7. doi:10.1007/s00384-012-1498-3
54. Thakur A, Fonkalsrud EW, Buchmiller T, French S. Surgical treatment of severe colonic inertia with restorative proctocolectomy. Am Surg (2001) 67:36-40
55. Di Lorenzo C, Flores AF, Reddy SN, Hyman PE. Use of colonic manometry to differentiate causes of intractable constipation in children. J Pediatr (1992) 120:690-5. doi:10.1016/S0022-3476(05)80229-X
56. Pemberton JH, Rath DM, Ilstrup DM. Evaluation and surgical treatment of severe chronic constipation. Ann Surg (1991) 214:403-11. doi:10.1097/00000658-199110000-00005
57. Zutshi M, Hull TL, Trzcinski R, Arvelakis A, Xu M. Surgery for slow transit constipation: are we helping patients? Int J Colorectal Dis (2007) 22:265-9. doi:10.1007/s00384-006-0189-3
58. Thomas GP, Dudding TC, Rahbour G, Nicholls RJ, Vaizey CJ. Sacral nerve stimulation for constipation. Br J Surg (2013) 100:174-81. doi:10.1002/bjs.8944
59. Lunniss PJ, Gladman MA, Hetzer FH, Williams NS, Scott SM. Risk factors in acquired faecal incontinence. J R Soc Med (2004) 97:111-6. doi:10.1258/jrsm.97.3.111
60. Bharucha AE, Fletcher JG, Melton LJ, Zinsmeister AR. Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case-control study. Am J Gastroenterol (2012) 107:902-11. doi:10.1038/ajg.2012.45
61. Levin A, Cohen MJ, Mindrul V, Lysy J. Delayed fecal incontinence following surgery for anal fissure. Int J Colorectal Dis (2011) 26:1595-9. doi:10.1007/s00384-011-1284-7
62. Barraclough LH, Routledge JA, Farnell DJJ, Burns MP, Swindell R, Livsey JE, et al. Prospective analysis of patient-reported late toxicity following pelvic radiotherapy for gynaecological cancer. Radiother Oncol (2012) 103:327-32. doi:10.1016/j.radonc.2012.04.018
63. Bharucha AE, Seide BM, Zinsmeister AR. The effects of clonidine on symptoms and anorectal sensorimotor function in women with faecal incontinence. Aliment Pharmacol Ther (2010) 32:681-8. doi:10.1111/j.1365-2036.2010.04391.x
64. Rey E, Choung RS, Schleck CD, Zinsmeister AR, Locke GR, Talley NJ. Onset and risk factors for fecal incontinence in a US community. Am J Gastroenterol (2010) 105:412-9. doi:10.1038/ajg.2009.594
65. Tantiphlachiva K, Attaluri A, Valestin J, Yamada T, Rao SSC. Translumbar and transsacral motor-evoked potentials: a novel test for spino-anorectal neuropathy in spinal cord injury. Am J Gastroenterol (2011) 106:907-14. doi:10.1038/ajg.2010.478
66. Bohle B, Belvis F, Vial M, Maestre Y, Pera M, Castillo M, et al. Menopause and obstetric history as risk factors for fecal incontinence in women. Dis Colon Rectum (2011) 54:975-81. doi:10.1097/DCR.0b013e31821c404a
67. Haadem K, Ling L, Fernö M, Graffner H. Estrogen receptors in the external anal sphincter. Am J Obstet Gynecol (1991) 164:609-10. doi:10.1016/S0002-9378(11)80032-3
68. Knudsen UB, Laurberg S, Danielsen CC. Age-related changes in the striated anal sphincter in female rats. A quantitative morphometric study. Scand J Gastroenterol (1991) 26:347-52. doi:10.3109/00365529109025053
69. Parks AG. Royal society of medicine, section of proctology; meeting 27 November 1974. President's address. Anorectal incontinence. Proc R Soc Med (1975) 68:681-90
70. Rao SSC, Coss-Adame E, Tantiphlachiva K, Attaluri A, Remes-Troche JM. Translumbar and transsacral magnetic neuro-stimulation for the assessment of neuropathy in fecal incontinence. Dis Colon Rectum (2013) (in press)
71. Snooks SJ, Setchell M, Swash M, Henry MM. Injury to innervation of pelvic floor sphincter musculature in childbirth. Lancet (1984) 2:546-50. doi:10.1016/S0140-6736(84)90766-9
72. Tetzschner T, Sørensen M, Lose G, Christiansen J. Anal and urinary incontinence in women with obstetric anal sphincter rupture. Br J Obstet Gynaecol (1996) 103:1034-40. doi:10.1111/j.1471-0528.1996.tb09557.x
73. Brouwer R, Duthie G. Sacral nerve neuromodulation is effective treatment for fecal incontinence in the presence of a sphincter defect, pudendal neuropathy, or previous sphincter repair. Dis Colon Rectum (2010) 53:273-8. doi:10.1007/DCR.0b013e3181ceeb22
74. Remes-Troche JM, Rao SSC. Neurophysiological testing in anorectal disorders. Expert Rev Gastroenterol Hepatol (2008) 2:323-35. doi:10.1586/17474124.2.3.323
75. Remes-Troche JM, Tantiphlachiva K, Attaluri A, Valestin J, Yamada T, Hamdy S, et al. A bi-directional assessment of the human brain-anorectal axis. Neurogastroenterol Motil (2011) 23(240-8):e117-8. doi:10.1111/j.1365-2982.2010.01619.x
76. Rao SS, Read NW, Davison PA, Bannister JJ, Holdsworth CD. Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology (1987) 93:1270-5
77. Read NW, Abouzekry L, Read MG, Howell P, Ottewell D, Donnelly TC. Anorectal function in elderly patients with fecal impaction. Gastroenterology (1985) 89:959-66
78. Rao SSC, Tuteja AK, Vellema T, Kempf J, Stessman M. Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol (2004) 38:680-5. doi:10.1097/01.mcg.0000135929.78074.8c
79. Sze EHM, Hobbs G. Efficacy of methylcellulose and loperamide in managing fecal incontinence. Acta Obstet Gynecol Scand (2009) 88:766-71. doi:10.1080/00016340902993320
80. Omar MI, Alexander CE. Drug treatment for faecal incontinence in adults. Cochrane Database Syst Rev (2013) 6:CD002116. doi:10.1002/14651858.CD002116.pub2
81. Bharucha AE, Fletcher JG, Camilleri M, Edge J, Carlson P, Zinsmeister AR. Effects of clonidine in women with fecal incontinence. Clin Gastroenterol Hepatol (2013). doi:10.1016/j.cgh.2013.06.035
82. Norton C, Cody JD. Biofeedback and/or sphincter exercises for the treatment of faecal incontinence in adults. Cochrane Database Syst Rev (2012) 7:CD002111. doi:10.1002/14651858.CD002111.pub3
83. Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence. Dis Colon Rectum (2009) 52:1730-7. doi:10.1007/DCR.0b013e3181b55455
84. Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev (2013) 2:CD007959. doi:10.1002/14651858.CD007959.pub3
85. Graf W, Mellgren A, Matzel KE, Hull T, Johansson C, Bernstein M. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet (2011) 377:997-1003. doi:10.1016/S0140-6736(10)62297-0
86. La Torre F, de la Portilla F. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence. Colorectal Dis (2013) 15:569-74. doi:10.1111/codi.12155
87. Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet (1995) 346:1124-7. doi:10.1016/S0140-6736(95)91799-3
88. Tan E, Ngo N-T, Darzi A, Shenouda M, Tekkis PP. Meta-analysis: sacral nerve stimulation versus conservative therapy in the treatment of faecal incontinence. Int J Colorectal Dis (2011) 26:275-94. doi:10.1007/s00384-010-1119-y
89. Maeda Y, Lundby L, Buntzen S, Laurberg S. Outcome of sacral nerve stimulation for fecal incontinence at 5 years. Ann Surg (2013). doi:10.1097/SLA.0b013e31829d3969
90. Vaizey CJ, Kamm MA, Turner IC, Nicholls RJ, Woloszko J. Effects of short term sacral nerve stimulation on anal and rectal function in patients with anal incontinence. Gut (1999) 44:407-12. doi:10.1136/gut.44.3.407
91. Patton V, Wiklendt L, Arkwright JW, Lubowski DZ, Dinning PG. The effect of sacral nerve stimulation on distal colonic motility in patients with faecal incontinence. Br J Surg (2013) 100:959-68. doi:10.1002/bjs.9114
92. Sheldon R, Kiff ES, Clarke A, Harris ML, Hamdy S. Sacral nerve stimulation reduces corticoanal excitability in patients with faecal incontinence. Br J Surg (2005) 92:1423-31. doi:10.1002/bjs.5111
93. Harris ML, Singh S, Rothwell J, Thompson DG, Hamdy S. Rapid rate magnetic stimulation of human sacral nerve roots alters excitability within the cortico-anal pathway. Neurogastroenterol Motil (2008) 20:1132-9. doi:10.1111/j.1365-2982.2008.01153.x
94. Felt-Bersma RJ, Szojda MM, Mulder CJ. Temperature-controlled radiofrequency energy (SECCA) to the anal canal for the treatment of faecal incontinence offers moderate improvement. Eur J Gastroenterol Hepatol (2007) 19:575-80. doi:10.1097/MEG.0b013e32811ec010
95. Takahashi-Monroy T, Morales M, Garcia-Osogobio S, Valdovinos MA, Belmonte C, Barreto C, et al. SECCA procedure for the treatment of fecal incontinence: results of five-year follow-up. Dis Colon Rectum (2008) 51:355-9. doi:10.1007/s10350-007-9169-0
96. Frascio M, Mandolfino F, Imperatore M, Stabilini C, Fornaro R, Gianetta E, et al. The SECCA procedure for faecal incontinence: a review. Colorectal Dis (2014) 16(3):167-72. doi:10.1111/codi.12403
97. Glasgow SC, Lowry AC. Long-term outcomes of anal sphincter repair for fecal incontinence: a systematic review. Dis Colon Rectum (2012) 55:482-90. doi:10.1097/DCR.0b013e3182468c22
98. Zutshi M, Tracey TH, Bast J, Halverson A, Na J. Ten-year outcome after anal sphincter repair for fecal incontinence. Dis Colon Rectum (2009) 52:1089-94. doi:10.1007/DCR.0b013e3181a0a79c
99. Johnson E, Carlsen E, Steen TB, Backer Hjorthaug JO, Eriksen MT, Johannessen H-O. Short-and long-term results of secondary anterior sphincteroplasty in 33 patients with obstetric injury. Acta Obstet Gynecol Scand (2010) 89:1466-72. doi:10.3109/00016349.2010.519019
100. Mevik K, Norderval S, Kileng H, Johansen M, Vonen B. Long-term results after anterior sphincteroplasty for anal incontinence. Scand J Surg (2009) 98:234-8
101. Edden Y, Wexner SD. Therapeutic devices for fecal incontinence: dynamic graciloplasty, artificial bowel sphincter and sacral nerve stimulation. Expert Rev Med Devices (2009) 6:307-12. doi:10.1586/erd.09.10
102. Tillin T, Gannon K, Feldman RA, Williams NS. Third-party prospective evaluation of patient outcomes after dynamic graciloplasty. Br J Surg (2006) 93:1402-10. doi:10.1002/bjs.5393
103. Wexner SD, Baeten C, Bailey R, Bakka A, Belin B, Belliveau P, et al. Long-term efficacy of dynamic graciloplasty for fecal incontinence. Dis Colon Rectum (2002) 45:809-18. doi:10.1007/s10350-004-6302-1
104. Thornton MJ, Kennedy ML, Lubowski DZ, King DW. Long-term follow-up of dynamic graciloplasty for faecal incontinence. Colorectal Dis (2004) 6:470-6. doi:10.1111/j.1463-1318.2004.00714.x
105. Darnis B, Faucheron J-L, Damon H, Barth X. Technical and functional results of the artificial bowel sphincter for treatment of severe fecal incontinence: is there any benefit for the patient? Dis Colon Rectum (2013) 56:505-10. doi:10.1097/DCR.0b013e3182809490
106. Wong MTC, Meurette G, Stangherlin P, Lehur P-A. The magnetic anal sphincter versus the artificial bowel sphincter: a comparison of 2 treatments for fecal incontinence. Dis Colon Rectum (2011) 54:773-9. doi:10.1007/DCR.0b013e3182182689
107. Wexner SD, Jin HY, Weiss EG, Nogueras JJ, Li VKM. Factors associated with failure of the artificial bowel sphincter: a study of over 50 cases from Cleveland clinic Florida. Dis Colon Rectum (2009) 52:1550-7. doi:10.1007/DCR.0b013e3181af62f8
108. Wong MTC, Meurette G, Wyart V, Glemain P, Lehur P-A. The artificial bowel sphincter: a single institution experience over a decade. Ann Surg (2011) 254:951-6. doi:10.1097/SLA.0b013e31823ac2bc
109. Lehur P-A, McNevin S, Buntzen S, Mellgren AF, Laurberg S, Madoff RD. Magnetic anal sphincter augmentation for the treatment of fecal incontinence: a preliminary report from a feasibility study. Dis Colon Rectum (2010) 53:1604-10. doi:10.1007/DCR.0b013e3181f5d5f7
110. Barussaud M-L, Mantoo S, Wyart V, Meurette G, Lehur P-A. The magnetic anal sphincter in faecal incontinence: is initial success sustained over time? Colorectal Dis (2013) 15:1499-503. doi:10.1111/codi.12423
111. Wong MTC, Meurette G, Wyart V, Lehur P-A. Does the magnetic anal sphincter device compare favourably with sacral nerve stimulation in the management of faecal incontinence? Colorectal Dis (2012) 14:e323-9. doi:10.1111/j.1463-1318.2012.02995.x